Skip to content

Ambulatory CPAP Titration in Moderate Obstructive Sleep Apnea

Ambulatory CPAP Titration in Moderate Obstructive Sleep Apnea

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04128930
Acronym
ATMOS
Enrollment
100
Registered
2019-10-16
Start date
2019-10-14
Completion date
2021-12-31
Last updated
2024-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep Apnea, Obstructive

Brief summary

The aim of this trial is to compare two different ways of CPAP titration: CAP titration with fixed pressure vs. auto-titrating CPAP.

Detailed description

Continuous positive airway pressure (CPAP) for the treatment of moderate obstructive sleep apnea (OSA) is only reimbursed in Belgium after in-laboratory overnight titration. Nevertheless, in a recent clinical practice guideline of the AASM, it is recommended that PAP therapy can be initiated using either in-laboratory titration or auto-titrating CPAP (APAP) at home in OSA patients without significant comorbidities. Indeed, several studies evaluated the impact of titration with APAP at home in these patients and showed that the outcome is comparable with in-hospital titration. Up to now, evidence for home titration with fixed CPAP (and follow-up via telemonitoring) is very limited. The use of sleep laboratory space is costly and limits access for diagnostic studies. This study aims to evaluate whether CPAP titration at home with fixed CPAP produces outcomes equal to those following APAP titration.

Interventions

DEVICEPAP titration at home

Fixed CPAP or APAP titration at home

Sponsors

Universitaire Ziekenhuizen KU Leuven
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* moderate OSA (obstructive AHI 15-30/u on initial PSG)

Exclusion criteria

* Presence of hypoventilation * Presence of central sleep apnea (central AHI ≥ 15)

Design outcomes

Primary

MeasureTime frameDescription
CPAP adherence3 monthsUsage of the device (mean number of hours/day)

Secondary

MeasureTime frameDescription
Residual apnea/hypopnea index2 weeksResidual respiratory events during treatment with optimal CPAP pressure during PSG
Mask leaks2 weeksObjective leaks (L/min) during CPAP treatment
Proportion of good titration2 weeksNumber of patients with residual AHI \< 10 (objectivated with PSG)
Residual device AHI3 monthsResidual AHI as determined from device data
Effective pressure level2 weeksOptimal pressure of CPAP therapy
Blood pressure3 monthsBlood pressure measurement
Pittsburgh Sleep Quality Index (PSQI)3 monthsSleep quality (range: 0-21 - higher score means worse outcome)
36-Item Short Form Health Survey3 monthsQuality of life (range: 0-100 - higher score means better outcome)
Hospital contacts3 monthsNumber of contacts with the hospital
Epworth Sleepiness Scale3 monthsDaytime sleepiness (range: 0-24 - higher score means worse outcome)

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026